Rebounding research and development returns spell success for local pharmaceutical companies, report shows.

Autor:	Neber, Jacqueline (AUTHOR)
Předmět:	PHARMACEUTICAL industry, RESEARCH & development
Zdroj:	Crain's New York Business. 5/6/2024, Vol. 40 Issue 18, p22-22. 1p.
Abstrakt:	According to a report from Deloitte, large pharmaceutical companies in New York and New Jersey saw a rebound in their returns on research and development (R&D) investments in 2023. The report found that projected returns on investment climbed to 4%, a significant increase from the previous year's record-low of 1.2%. This positive performance was driven by companies bringing more drug candidates into the later stages of development. The report also highlighted the growing interest in oncology and infectious disease drugs, as well as the use of artificial intelligence in drug development. Despite some concerns about rising costs and regulatory challenges, the pharmaceutical industry in the metropolitan area is well-positioned for continued success. [Extracted from the article]
Databáze:	Regional Business News
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.